Aventis Merger Would Bring New Blood To Novartis’ Cardiology R&D
A merger with Aventis would invigorate Novartis' cardiology portfolio with the addition of an early-stage cardiovascular pipeline
You may also be interested in...
FDA has cleared Novartis' angiotensin II receptor blocker Diovan (valsartan) for first-line use in the treatment of heart failure using data generated by AstraZeneca for its ARB Atacand (candesartan)
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011